Mouse study links GIP receptor effects to two brain regions, offering clues for tirzepatide

A study in mice has identified two separate brain regions that appear to explain a long-standing puzzle about GIP receptor drugs: turning the receptor on and blocking it can both add weight loss when combined with a GLP-1 medicine ^[1]. The work was published in Nature Metabolism, and Nature Reviews Endocrinology published a research highlight on the findings on 19 August 2026 ^[1][2].

The puzzle concerns tirzepatide (Mounjaro, Zepbound), which activates both the GLP-1 receptor and the GIP receptor and produces greater weight loss than GLP-1 receptor agonism alone ^[1]. Yet in preclinical and clinical studies, adding a GIP receptor antagonist — the opposite approach — to GLP-1 receptor agonism also caused additional weight loss ^[1]. The authors cite once-monthly maridebart cafraglutide, tested in a phase 2 trial published in the New England Journal of Medicine in 2025, as an example of the antagonist approach ^[1].

To sort this out, the researchers used mice with a floxed Gipr gene and injected a virus carrying Cre-recombinase into one of two brain areas, deleting the GIP receptor in either the area postrema (GiprAP-KO mice) or the hypothalamus (Giprhypo-KO mice). Control mice received a virus carrying GFP instead. The team then compared body weight and food intake responses to GIP receptor agonists and antagonists, given alone and in combination with the GLP-1 receptor agonist liraglutide ^[1].

In the area postrema group, control mice treated with acyl-GIP had significantly reduced food intake and body weight, while GiprAP-KO mice showed no such reduction; diet-induced obese GiprAP-KO mice were also unaffected by acyl-GIP ^[2]. These mice showed partial protection against diet-induced obesity and a reduced ability of acyl-GIP to prevent avoidance triggered by peptide YY ^[1]. Weight loss from liraglutide was comparable in GiprAP-KO and control mice, and adding a GIP receptor antagonist peptide produced similar extra weight loss in both groups ^[1].

In the hypothalamus group, the pattern was reversed. Giprhypo-KO mice had normal appetite suppression from acyl-GIP but lost more weight on liraglutide than control mice, and the knockout abolished the extra weight loss normally seen when a GIP receptor antagonist is combined with liraglutide. The authors report that this effect is not mediated by preproglucagon neurons in the nucleus tractus solitarius ^[1]. GIP receptor antagonism and the hypothalamic knockout also made mice more sensitive to weight loss from cagrilintide, an amylin receptor agonist ^[1].

The two regions differ in ways that may matter for drug design. The area postrema sits outside the blood-brain barrier and has a high density of Gipr-expressing cells, most of them GABAergic, while many Gipr-expressing neurons in the hypothalamus lie behind the blood-brain barrier and include both glutamatergic and GABAergic cells ^[1]. GIP also appears to reduce nausea-related behaviors, an effect attributed to Gipr-expressing cells in the brainstem and area postrema ^[1].

Why it matters for patients

Obesity drug development has increasingly focused on pairing a GLP-1 signal with a second hormone signal. This study suggests the two GIP strategies are not a contradiction but act in different places, with the area postrema handling appetite suppression from GIP receptor activation and the hypothalamus handling the extra weight loss from GIP receptor blockade ^[1][2]. That could inform which combinations companies pursue next.

It does not change anything about currently approved medicines. The experiments were done in mice, and no human data in this study address whether the same two regions control appetite or weight in people. Whether these findings predict which combinations work better in patients, or how they relate to side effects such as nausea, has not been reported. The area postrema is also involved in nausea and vomiting, but this study did not test whether blocking GIP receptors in people affects those symptoms.

What happens next

No human study designed to test whether the same brain regions matter in people has been reported, and no timeline for such research has been disclosed ^[1][2]. The Nature Reviews Endocrinology highlight describing the mouse findings was published on 19 August 2026, with an issue date of October 2026 ^[2].